Browse the latest research summaries in the field of oncology for spinal cord injury patients and caregivers.
Showing 101-110 of 144 results
The EMBO Journal, 2023 • February 17, 2023
This study identifies IFITM1 as a key repressor of brain metastatic colonization in lung cancer. Loss of IFITM1 promotes brain colonization, while high IFITM1 expression activates microglia and enhanc...
KEY FINDING: Loss of IFITM1 promotes brain colonization of human lung cancer cells, identified through in vivo genome-wide CRISPR-Cas9 screening.
The Journal of Spinal Cord Medicine, 2015 • January 1, 2015
This study investigates the effectiveness of inpatient rehabilitation for patients with malignant spinal cord compression (MSCC) compared to those with non-traumatic spinal cord injury (NT-SCI). The r...
KEY FINDING: Patients with MSCC showed significant improvement in the Functional Independence Measure (FIM) scores during inpatient rehabilitation.
Global Spine Journal, 2025 • January 1, 2023
This retrospective cohort study compared neurological outcomes and retreatment rates in multiple myeloma patients with high-grade ESCC treated with radiotherapy or surgery. The study found that surgic...
KEY FINDING: Surgical treatment was associated with significantly lower odds for neurological deterioration compared to radiotherapy (OR = .15; 95% CI .05 - .44; P < .01).
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2013 • January 1, 2013
This case report describes the successful treatment of a small intramedullary schwannoma using minimally invasive hemilaminectomy. The patient experienced symptom improvement and no tumor recurrence d...
KEY FINDING: Intramedullary schwannomas can be successfully removed via minimally invasive hemilaminectomy, preserving spinal stability.
Genome Medicine, 2023 • December 2, 2023
The study introduces comboSC, a computational prototype for personalized cancer combination therapy optimization using single-cell transcriptomes. ComboSC stratifies individual patient samples based o...
KEY FINDING: ComboSC can predict potential drug combinations for experimental validation and clinical usage using the single-cell transcriptome.
Neural Regeneration Research, 2014 • January 1, 2014
This retrospective study evaluated the impact of early rehabilitation on neurofunctional outcomes in 70 pediatric patients who underwent spinal tumor surgery. The patients received rehabilitation trea...
KEY FINDING: Early rehabilitation significantly improved sensory function, motor function, and activity of daily living in pediatric children after spinal tumor surgery.
Orthopaedic Surgery, 2019 • October 1, 2019
This study aimed to identify prognostic factors and develop nomograms for predicting the overall survival (OS) and cause-specific survival (CSS) of patients with non-metastatic chondrosarcoma using da...
KEY FINDING: Age, gender, tumor size and extension, surgery, histological grade, and subtype were identified as independent prognostic factors for both overall survival (OS) and cause-specific survival (CSS).
Neural Regen Res, 2018 • March 1, 2018
This study evaluated the effects of 125I radioactive seed implantation on the spinal cord of rabbits using diffusion tensor imaging (DTI) and pathological analysis. The results indicated that higher r...
KEY FINDING: Increased radiation dose (D90) correlated with aggravated pathological damage of neurons and microvessels in the gray matter and white matter.
PLoS ONE, 2013 • September 10, 2013
This study identifies SOCS1 as a novel target gene of the Hh/GLI signaling pathway in epidermal and neural tumor cells. The Hh/GLI pathway, when activated, upregulates SOCS1 expression. Upregulation o...
KEY FINDING: SOCS1 is identified as a direct transcriptional target of Hh/GLI signaling in human keratinocytes and medulloblastoma cells.
Frontiers in Oncology, 2019 • February 1, 2019
This systematic review analyzed 33 studies on molecular targeted therapy (MTT) for chordoma, a rare bone malignancy affecting the spine and skull base. The review identified imatinib and erlotinib as ...
KEY FINDING: Imatinib and erlotinib were the most frequently used molecular targeted inhibitors (MTIs) for chordoma.